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BY H. STACY VEREEN, MD
A Geography and Culture Study for Those
of You Attending the CAMA Annual Meet-
ing in Amsterdam
HOLLAND— more correctly, theNetherlands— is nestled betweenGermany to the east and Belgium to
the south and borders on the North Sea to the
west. In land area, the Netherlands (meaning
"lowlands") is one of the smallest countries of
Europe (about half the size of the state of
Maine). In economic and cultural terms how-
ever, Holland is one of the principal countries
of not only Europe, but also the world.
The largest city, Amsterdam, is an enigma
that almost defies description. When one
thinks of art and the Dutch Masters
(Rembrandt, Terborch, Van Ruysdael, and
Van Gogh, to name a few) Amsterdam cer-
tainly comes to mind. In fact, all the way
from diamond cutting to windmills to
wooden shoes, the Dutch people are famous
well beyond their numbers.
It is especially befitting that we find our
Annual 2002 International Scientific Meeting
in this delightful country and specifically in
its largest city, Amsterdam. After all, medicine
and aviation are what we are about and, to a
great extent, so is Holland. One need only
diink of the microscope and the electrocardio-
gram as examples of great medical contributions.
It is universally acknowledged that the
Dutch took their leadership role in seafaring
adventure smoothly and seemingly effortlessly
into the world of aviation. Many of you have
visited Amsterdam and will appreciate the dif-
ficulty in attempting to describe this multifac-
eted jewel within the scope of a newsletter
Smallpox: Mass
Vaccinations or Not?
BY PATTI PATTERSON, MD, MPH
AND JAMES A. REINARZ, MD
J""~| j tiE LAST CASE OF SMALLPOX in the United
States occurred in 1949, and the last
_JL naturally occur-
ring case in the world was
in Somalia in 1977. The
disease was eradicated by
a worldwide vaccination
program. That public
health triumph has now
become a major problem.
Half a century ago,
smallpox would have
been much less of a bio-
terrorist threat because
the majority of the world's population was
immune to the disease. With the eradica-
tion of the disease and discontinuation of
the vaccine program because it was no
longer deemed necessary, the majority of the
world's population is now susceptible to this
infection. In the April 25, 2002, edition of
the New England Journal of Medicine, Dr.
Anthony S. Fauci calls for informed debate
on the issue of universal vaccination for
smallpox (1). This discussion among pub-
lic health officials, homeland security ex-
perts, and medical professionals is occur-
ring in a context that has never been en-
countered in health policy development.
Unfortunately, the discussion seems to be
colored more by the unknown than by the
known. We do not know the true risk of
this virus being used as a biological weapon.
Massive amounts have been produced and
were "weaponized," and the virus remains
Continued on page 6 Continued on page 12
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The President's Musings
BY ROBIN DODGE, MD
ANNUAL ClVIL AVIATION
Medical Association meeting
in Amsterdam is just over two
months away and initial advance
registrations are looking respect-
able. If you have yet to make your
reservations or even decide whether
or not you are going to the
meeting, it is not too late.
This year it will be possible
to purchase "day tickets" in
case you can only make it
for a short period and do
not want to pay the full
registration fee.
Although the Amsterdam meeting is not yet here,
in keeping with CAMA's new approach to meeting
planning the wheels are already in motion for next year's
meeting in Seattle. About mid-month, the co-planners
for the meeting will have received an e-mail from me
reminding them of our initial discussions and encourag-
ing them to begin setting the program agenda in earnest.
Also, it is time to begin planning the CAMA-sponsored
Sunday afternoon event in conjunction with next year's
annual AsMA meeting in San Antonio. The first time
this was done was in Montreal this past May. The audi-
ence was small, but the meeting was better attended than
we had hoped for. With sufficient planning and advance
If you have yet to make your reservations or
even decide whether or not you are going to
the meeting, it is not too late.
notice, it is anticipated that next year will see the
attendance grow. The initial impetus for this event sprang
from the desire to have CAMA increase its presence and
interaction with AsMA. A driving force behind this
thought was the idea that in today's world it is necessary
for greater cooperation between groups of like interest to
share valuable resources.
Related to the idea of a greater CAMA activity in
conjunction with the annual AsMA meeting is the
question of a closer CAMA-AsMA interaction. This
question comes up every once in awhile and has been
debated several times by
the CAMA Executive.
There is a good reason for
the two organizations to
remain independent and
to provide separate ser-
vices to their respective
memberships. For a more detailed overview of this sub-
ject, I would direct you to the CAMA Web site to read
the president's words for the month of August 2002.
In reviewing our Web site statistics, it appears that
few members are taking advantage of the Members-
Only section. Consequently, current plans for updat-
ing and modifying that portion of the site are being
put on hold.
As always, the Executive remain committed to pro-
viding services the membership wishes to see. Thus if
you have suggestions, comments, or thoughts that you
would like to pass on to the Executive, you are en-
couraged to contact any member of the Executive,
Board of Trustees, Jim Harris, or myself. FP
Educating Homeland Security
JAMES R. ALMAND, MD
A more severe absence of public instruction and education on bioterrorism exists....and can evolve to a
critical potential unless addressed soon.
BIOTERRORISM IS DIFFICULT TO DETECT. This is theprincipal tool of the terrorist, who usually goesundetected. Biowarfare is usually colorless, odor-
less and secret. Its detection is difficult and usually too
late for effective protection of the populace. Critical
disease may rapidly develop and progress to an uncon-
trollable level before recognition.
The American public requires rapid and careful edu-
cation on bioterrorism and biowarfare protection. The
critical risk to the country in the event of a terrorist at-
tack was demonstrated on September 11. The immediate
recognition of bioterrorism can be delayed to a degree,
rendering successful recovery questionable.
To date, there has been a slow, positive development
of physician knowledge and recognition of bioterrorism
among the profession. A more severe absence of public
instruction and education on bioterrorism exists. This
deficiency can evolve to a critical potential unless
addressed soon.
Critics already argue that the war on terrorism is pull-
ing too much money from domestic programs for the
benefit of the country's defense, but compare today's cost
of 3.3 percent of the gross national product for defense
(the same as 1997) to World War II defense budget of 38
Continued on page 11
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How TO GET THERE FROM ALMOST ANYWHERE
If you plan to attend the Civil Avia-tion Medical Association's annual
meeting in Amsterdam, this information
will be useful to you when deciding
whether to travel by train, bus, taxi, or
rental car from the Schiphol
(Amsterdam) Airport to the Amsterdam
Central Region. Bas Voorsluijs, our cor-
respondent in Amsterdam, has e-mailed
the most current information for your
convenience. Here are your choices:
By train. Travelling to Amsterdam
Airport Schiphol by train is not only
fast but also very
convenient. You can
travel to Schiphol
from any railway sta-
tion in the Nether-
lands. In most cases, you will not need
to change trains more than once. You
will arrive under Schiphol Plaza, in the
central hall of the terminal. This is lo-
cated near the hotel check-in desks so
that you can register immediately and
also check your baggage.
On weekends and on public holi-
days, trains run on different time-
tables. From Schiphol Airport, the
train runs on a 10 to 15-minute sched-
ule to Amsterdam's Central Railway
Station. One-way ticket costs Euro
2,90-4,50. It takes about 15-20 min-
utes from Schiphol Airport to the Cen-
tral Railway Station. From there, you
can walk (walking distance is 830
meters, about 10 minutes), or take a
taxi or tram.
(After the meeting, you can take a
train to the airport from the Terminal
NS —Dutch Railways. Ticket desks
and ticket machines are located in the
Terminal Building.)
By bus. There are many direct bus
services between
Schiphol and places
in the region. Travel
times to and from
Schiphol are rarely
longer than 30
minutes . All bus services stop at
Schiphol Plaza, so you can get on or
off the bus right in front of the Termi-
nal Building. There are also rush-hour
and night services with a limited sched-
ule for commuters.
By Schiphol Travel Taxi. A national




small taxi van will
collect you from
any address in the Netherlands on the
date and time agreed with you, with-
out any transfers and without having
to lug your suitcase around with you.
Costs for Postal Code 1012
(Krasnapolsky): Roundtrip adult fare
is EUR 40.00; one-way adult fare EUR
22.00. You can book this taxi in ad-
vance on the In te rne t : h t tp : / /
www.schiphol.nl/.
By rental car. October 9-12 prices
vary from EUR 99
(Mini 2/4 Door
(MCMN), 9999
free + .39/km for
extra; no air condi-
t ioning, manual
shift to EUR 150.00; economy 2/4
door (ECMN), unlimited mileage; no
air conditioning; manual shift. fP
Thinking about attending the annual meeting in Amsterdam?
You can still make your reservations, if you hurry!
Call 405-840-0199
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The Changing Face of Civil Aviation Medicine, Part
An Industry in Rapid Transition Seeks to Redefine Itself
THE SECOND OF A TWO-PART SERIES, BY CHARLES E. BILLINGS, MD, THE OHIO STATE UNIVERSITY
You can't answer questions facing the aviation industry analytically. The only way to approach them is
empirically, by sneaking up on them. That's what has been done, thus far successfully, with terminal area
separation minima. But we have to recognize that bad outcomes are rare in a well-organized system. So it
may be quite awhile before something really scary happens, even if we have increased the probability of a bad
outcome from .001 to, say, .01, or more likely from .0001 to .001.
An Industry in Continual Transition
CVIL AVIATION HAS UNDERGONE MANY profoundhanges in the last decade, and some of thesehanges have profoundly affected not only our
pilots and controllers but nearly all of the people for whom
aviation is a livelihood and way of life. Some of them also
affect the customers who purchase the services of the avia-
tion system. I'd like to mention some that may be impor-
tant in helping you to serve and support these people,
many of whom are your patients or customers as well.
(An aside: Please don't be upset at my use of the word
"customer." Aviation and medicine are both very com-
plex enterprises, but each has really only a single product
that it sells to customers. Civil aviation provides trans-
portation services for passengers and cargo; it has no other
reason for being. Medicine provides services to restore,
maintain and enhance human health; it too has no other
reason for being. Both domains try to provide their prod-
uct economically, for both are demand-driven, for-profit
enterprises. And I must observe that at the moment, de-
spite all our problems, we're doing rather better than is
air transport, whose losses this year were already in the
billions before the week of September 10th, during which
they lost another 500 million dollars.)
Regional and especially commuter airlines were largely
flying turboprop airplanes at medium altitudes in 1991.
Today, great numbers of commuter flights are in very ca-
pable 40-70 seat, high- performance jets. As an example,
325 regional jets were ordered in this country last year,
against less than 40 turboprops. This change has pro-
foundly affected the US aviation system. Turboprops usu-
ally fly below 25,000 feet, whereas the regional jets fly at
the same higher altitudes as larger jets, further crowding
high-altitude airspace, which was already laboring under
the demands placed on it by the large airlines. Some
smaller jets aggravate the high-altitude congestion prob-
lem because they cruise at somewhat slower speeds than
the larger airplanes, compounding in-trail separation prob-
lems for air traffic controllers.
Regional jets, placed in service at a time of high de-
mand for pilots and a diminishing pilot supply due to
contraction of military aviation, have strained the ability
of commuter carriers to crew them with experienced pi-
lots, and this ability was already strained by high pilot
turnover because of accelerated hiring of commuter pi-
lots by the major airlines. Flying high-performance air-
craft has placed increased workloads on these pilots and
others as well, because of increasing traffic density even
at higher altitudes. Controllers likewise face higher
workloads because of the added traffic, especially when
weather is unfavorable. The FAA has still been unable to
come up with coherent flight and duty time regulations
for flight crew, and, for that matter, cabin crew, who are
placed under stress both by many short flight segments
(average segment lengths are less than an hour and crews
must often fly 6-9 per day) and by very long segments
(the newest long-range wide body aircraft have ranges
above 15 hours during which they may fly more than
7000 miles). Both duty extremes impose their own physi-
ological and psychological strains on crewmembers, and
both are very tiring when performed several times each week.
Congestion is a phenomenon of our time. We know
that collaborative decision making between airlines and
Air Traffic Control traffic managers can appreciably im-
prove operator workload in the aviation system. The
workload problem is serious in many places and critical
in some. Cooperation is not helped by attitudes such as
that expressed by a vice president of the Air Transport
Association at the height of the delay crisis last year when
he said, "It's our job to schedule flights from place to
place to accommodate our customers. It's the FAA's job
to handle them when we schedule them." At that time,
the airlines were trying to schedule over 100 additional
Continued next page
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flights a day into LaGuardia, which was already operat-
ing beyond capacity and routinely running arrival delays
upwards of 90 minutes by late afternoon, even in clear
weather.
Some fairly draconian measures, along with better
weather, have helped this summer, but departure delays
can still exceed two hours. Passengers are still deeply dis-
satisfied with airline on- time performance, personal dis-
comfort, and sub-par service, and are still demanding
improvements that are unlikely to address their complaints
until the aviation infrastructure improves. There is an
abundance of stress for passengers, too, and at least some
of the "air rage" incidents probably reflect this.
We have seen an increased incidence of deep vein
thromboses in long-haul travel, and this too is hardly sur-
prising given the high-density seating that has been forced
on passengers by airlines trying to squeeze more yield out
of limited numbers of long-haul airplanes being operated
nearly at capacity (80% occupancy levels are routine dur-
ing summer transoceanic flights). All of this affects you,
because you are the physicians most likely to hear about
these problems, if anyone does. The vast majority of such
problems never surface, or become known only when a
particularly egregious incident is reported by the press.
But they are occurring on a daily basis.
To this melange of problems in a rapidly-changing air
transport environment, we can now add the residue of
the appalling tragedies of September 11th. Everyone was
hurt by the events of that day. I spent a week trying to get
back from Aspen to Columbus. My seventh confirmed
flight reservation finally worked for me, but I observed
500 or more prospective passengers awaiting an uncer-
tain future at just one airline's counters at Denver at 9:00
am on Sunday, and other airlines were facing the same
onslaught. I tried to contact another major carrier from
September ] 2th to 25th without ever getting to talk to a
living person before finally getting through at 5 am on
the 26th. Yet many airplanes are flying with 30% load
factors; people aren't canceling (in part because they can't
contact their airline by phone), so they're simply not show-
ing up for flights. Others who have continued to fly have
much higher levels of anxiety and face much longer
waits because of security procedures before even board-
ing their aircraft.
Fear of flying appears to be alive and flourishing, and
several smaller air carriers are now facing bankruptcy as a
result. Announced layoffs in the airline industry exceed
130,000, and about 20% of scheduled operations nation-
wide have been canceled. As a result, Boeing has an-
nounced that it will lay off 30,000 of its employees because
of canceled or delayed orders for new airplanes. Many of
these employees are your patients, and they may need
help more than those who stay, though the retained em-
ployees will certainly be asked for still greater productiv-
ity and sacrifices as a condition of continued employment,
and this will also lead to increased job stress for them.
I don't want to over-emphasize these problems. The
majority of airline passengers have put up with a good
deal of discomfort and inconvenience in the past three
years, and have continued to fly. But neither I nor any-
one else knows where their tolerance limits are, and we
are in the process of adding a fair amount of additional
inconvenience and discomfort, without many counter-
vailing benefits. This is another area in which we do not
know "how much hassle is too much," and we will only
find out empirically if passengers simply decide not to
utilize airline services. As a very frequent air traveler, I
think we're closer to trouble than we may think. And this
is not a problem that can be simply legislated away or
solved by lower fares, which wouldn't help much in
any event because of the financial troubles now being
faced by airlines.
Technology Changes
A couple of other changes concern me. Technology
has changed, too. As one instance that concerns most of
you, our certification system now relies on automated
transfer of medical information to an FAA Web site. I am
certain that this has lightened an unbearable load at the
Aeromedical Certification Division, which has been un-
derstaffed for years and has coped magnificently with the
shortcomings of the system within which it operates. For
those of you who see the same pilots every year and main-
tain good paper records, this is probably only one more
administrative bother to accompany the many other prob-
lems with which you deal on a daily basis. But when a
new airline pilot asks you for a medical exam, you are less
able than before to deal with this unknown quantity, be-
cause you do not have access to previous medical records
on this pilot.
So you do the examination, do the "paperwork," trans-
mit the data to FAA—and perhaps wonder what else the
pilot may have had that he or she didn't remember to tell
you about in the past medical history. Granted, that was
the situation before the system was automated—but we
could do better than this. Computerized records are not
that hard to search, and even a list of past medical
Concluded on page 15
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Amsterdam from page i
article. Amsterdam is on one hand, a city of staid, Old
World houses .. .a city of fine arts and classical music.
On the other hand, it is a city of tolerance and personal
freedom with ethnic backgrounds from all over the globe.
Amsterdam was the richest and most powerful city in the
world during the 17th century. Its worldwide trade led
Voltaire to call it "the storage depot of the world." But
today, Amsterdam is noted by many to be the "gateway
to Europe." Fine art has been replaced slowly but surely
by "design," the new canvas is the Internet, and the new
Amsterdammer is savvy and chic.
There are a few practical aspects of visiting Amsterdam.
The city is served by one of the most comfortable air-
ports in the world, Schiphol. It serves about 35 million
people per year. There is rail service from the airport to
the city. It's cheap and it's quick and if you get lost, just
ask someone, virtually everyone here speaks English.
From the looks of our CAMA social program, we will
be quite busy, with all sorts of interesting outings. But, if
you want to do a little exploring in your free time, there
are more places to see and things to do than I can explain
here. I do suggest the guidebook HOLLAND, published
by Fodor's for about $20.00. You can read all about the
sights of Amsterdam as well as side-trips to places like
Delft (as porcelain and "Delft blue"), Utrecht, or the
Keukenhof Gardens on the way to Leiden, or The Hague,
the seat of Government. Walks around the city are safe
and a night stroll along the canals is breathtaking. Tem-
peratures, even in October, are generally mild but late-
autumn sweaters, jackets, and hats are advised.
If you have previously visited Holland, by all means
bring your left-over guilders, but prepare to trade them
in for the brand new EU (Euro dollar). Law (you get one
Euro for every 2.2 guilders) fixes the exchange rate. You
can buy travelers cheques in Euro at home before you
arrive. This is advisable due to a lousy exchange rate at
the airport. As in most places, the best exchange rate is at
a bank. There are also ATM's all over the city.
If one word could describe CAMA's academic pro-
gram, planned social activit ies, and the city of
Amsterdam, the word that comes to mind is UNIQUE!
We hope you will register for this experience, and we
hope to greet you in Amsterdam. If you haven't sent in
your registration form, time is running out, so hurry.
PP
CAMA CONSULTANTS
To our new members and as a reminder to all: This is a list of more experienced AMEs that have volunteered to help
with troublesome certification cases. For involved questions, e-mail or fax is preferred. This list is NOT for use by airmen,
but solely for AMEs within the CAMA membership.
Frank H. Austin, MD EST
Phone: 703- 471-1769 Fax: 703-450-3104
E-mail: FHAustin@aol.com
Charles A. Berry, MD GST
Phone: 713-978-7755 Fax: 713-978-5001
E-mail: docchuckb@aol.com
A. Duane Catterson, MD CST
Phone: 281-873-0111 Fax: 281-873-0660
E-mail: cattersib@worldnet.att.net
Marc C. Eidson, MD CST
Phone: 817-599-9472 Fax: 817- 599-9472
E-mail: MARK@EIDSON.ORG
A.J. Parmet, MD CST
Phone: 816-561-3480 Fax: 816-561-4043
E-mail: AJParmet@cysource.com
Gordon L. Ritter, DO MST
Phone: 520-776-9830 Fax: 513-751-5660
E-mail: gordon@rittaire.com
Robert A. Stein, MD EST
Phone: 513-751-0080 Fax: 513-751-5660
E-mail: Bobxtein47@aol.com
M. Young Stokes III, MD CST
Phone 903-465-6707 Fax: 903-465-6744
E-mail: mysiii@flash.net




Mark Thoman, MD CST
Phone: 515-244-4229 Fax: 515-244-1131
E-mail: PARO1795@aol.com
John D. Hastings, MD CST
Phone: 918-747-7517 Fax: 918-742-7947
E-mail: hastings20@msn.com
H. Stacy Vereen, MD EST
Phone: 404-761-2166 Fax: 404-761-2168
E-mail: Stacyv@earthlink.net
STEREO OPTICAL, A TRUSTED NAME IN
VISION SCREENING FOR OVER 50 YEARS,
QPTEC? 2000/2500 VISION TESTER FEATURES
Forehead Rest Pressure Bar
Ensures proper patient position.
(Includes disposable forehead tissues.)
Controlled Lighting




Test vision on s horizontal
plane. Stimuli at 85, 70,
and 55 degrees temporal
and nasal.
Distance/Near Lens Systems
Two separate testing ports
for accurate distance and near testing.
Test at 32 indies for
intermediate testing,*
Lightweight, Portable
Built in handle for easy
transport.
•Mi. Side Access Doors
i For easy patient/instructor
interaction.
Near/Far Point Indicators
Illuminates at proper position





























Distance Letter Acuity Monocular/Binocular (20/200-20/20)
Pseudoisochromatic Color Perception
Near Letter Acuity Monocular/Binocular (20/100-20/20)
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of hives, and size of hives, in patients with chronic idiopathic urticaria fCIU) 12 years of age and older
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requiring mental alertness
I Safe for use in seasonal allergic rhinitis patients
with concomitant mild to moderate asthma
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— In studies with erythromycin, ketoconazole, azithromycin,
fluoxetine, and cimetidine
I Neither food nor grapefruit juice affected bioavailability
I The FAA medically qualifies pilots and air traffic controllers
using the product under special conditions
In allergic rhinitis, the most commonly reported adverse In chronic idiopathic urticaria, the most commonly
events included pharyngitis (4.1 %, placebo 2.0%), reported adverse events included headache
dry mouth (3.0%, placebo 1.9%), and fatigue (2.1%, (14%, placebo 13%), nausea (5%, placebo 2%),
placebo 1.2%). and fatigue (5%, placebo 1 %).
(desloratadine) 5mgTABLETS




Brief Summary (For full Prescribing Information, see package insert.)
INDICATIONS AND USAGE: Allergic Rhinitis: CLARINEX Tablets 5 mg are indicat-
ed for the relief of the nasal and non-nasal symptoms of allergic rhinitis (seasonal
and perennial) in patients 12 years of age and older.
Chronic Idiopathic Urticaria: CLARINEX Tablets are indicated for the symptomatic
relief of pruritus, reduction in the number of hives, and size of hives, in patients with
chronic idiopathic urticaria 12 years of age and older.
CONTRAINDICATIONS: CLARINEX Tablets 5 mg are contraindicated in patients
who are hypersensitive to this medication or to any of its ingredients, or to lorata-
dine.
PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility: The car-
cinogenic potential of desloratadine was assessed using loratadine studies. In an
18-month study in mice and a 2-year study in rats, loratadine was administered in
the diet at doses up to 40 mg/kg/day in mice (estimated desloratadine and deslor-
atadine metabolite exposures were approximately 3 times the AUC in humans at the
recommended daily oral dose) and 25 mg/kg/day in rats (estimated desloratadine
and desloratadine metabolite exposures were approximately 30 times the AUC in
humans at the recommended daily oral dose). Male mice given 40 mg/kg/day
loratadine had a significantly higher incidence of hepatocellular tumors (combined
adenomas and carcinomas) than concurrent controls. In rats, a significantly higher
incidence of hepatocellular tumors (combined adenomas and carcinomas) was
observed in males given 10 mg/kg/day and in males and females given
25 mg/kg/day. The estimated desloratadine and desloratadine metabolite exposures
of rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans
at the recommended daily oral dose. The clinical significance of these findings dur-
ing long-term use of desloratadine is not known.
In genotoxicity studies with desloratadine, there was no evidence of genotoxic
potential in a reverse mutation assay (Salmonella/E. coli mammalian microsome
bacterial mutagenicity assay) or in two assays for chromosomal aberrations
(human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow
micronucleus assay).
There was no effect on female fertility in rats at desloratadine doses up to
24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 130 times the AUC in humans at the recommended daily oral dose). A
male specific decrease in fertility, demonstrated by reduced female conception rates,
decreased sperm numbers and motility, and histopathologic testicular changes,
occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine
exposures were approximately 45 times the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3
mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 8 times the AUC in humans at the recommended daily oral dose).
Pregnancy Category C: Desloratadine was not teratogenic in rats at doses up to
48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures
were approximately 210 times the AUC in humans at the recommended daily oral
dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures
were approximately 230 times the AUC in humans at the recommended daily oral
dose). In a separate study, an increase in pre-implantation loss and a decreased
number of implantations and fetuses were noted in female rats at 24 mg/kg (esti-
mated desloratadine and desloratadine metabolite exposures were approximately
120 times the AUC in humans at the recommended daily oral dose). Reduced body
weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or
greater (estimated desloratadine and desloratadine metabolite exposures were
approximately 50 times or greater than the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on pup development at an oral dose of
3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 7 times the AUC in humans at the recommended daily oral dose).
There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response,
desloratadine should be used during pregnancy only if clearly needed.
Nursing Mothers: Desloratadine passes into breast milk, therefore a decision
should be made whether to discontinue nursing or to discontinue desloratadine,
taking into account the importance of the drug to the mother.
Pediatric Use: The safety and effectiveness of CLARINEX Tablets in pediatric
patients under 12 years of age have not been established.
Geriatric Use: Clinical studies of desloratadine did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported clinical experience has not identified differences
between the elderly and younger patients. In general, dose selection for an elderly
patient should be cautious, reflecting the greater frequency of decreased hepatic,
renal, or cardiac function, and of concomitant disease or other drug therapy, (see
CLINICAL PHARMACOLOGY - Special Populations).
Information for Patients: Patients should be instructed to use CLARINEX Tablets
as directed. As there are no food effects on bioavailability, patients can be instruct-
ed that CLARINEX Tablets may be taken without regard to meals. Patients should
be advised not to increase the dose or dosing frequency as studies have not demon-
strated increased effectiveness at higher doses and somnolence may occur.
ADVERSE REACTIONS: Allergic Rhinitis: In multiple-dose placebo-controlled tri-
als, 2,834 patients received CLARINEX Tablets at doses of 2.5 mg to 20 mg daily,
of whom 1,655 patients received the recommended daily dose of 5 mg. In patients
receiving 5 mg daily, the rate of adverse events was similar between CLARINEX and
placebo-treated patients. The percent of patients who withdrew prematurely due to
adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group.
There were no serious adverse events in these trials in patients receiving deslor-
atadine. All adverse events that were reported by greater than or equal to 2% of
patients who received the recommended daily dose of CLARINEX Tablets (5.0 mg
once-daily), and that were more common with CLARINEX Tablet than placebo, are
listed in Table 5.
Table 5
Incidence of Adverse Events Reported by > 2% of Allergic Rhinitis
Patients in Placebo-Controlled, Multiple-Dose Clinical Trials
Adverse Experience




















The frequency and magnitude of laboratory and electrocardiographs abnormali-
ties were similar in CLARINEX and placebo-treated patients.
There were no differences in adverse events for subgroups of patients as defined
by gender, age, or race.
Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic
idiopathic urticaria, 211 patients received CLARINEX Tablets and 205 received
placebo. Adverse events that were reported by greater than or equal to 2% of
patients who received CLARINEX Tablets and that were more common with
CLARINEX than placebo were (rates for CLARINEX and placebo, respectively):
headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%),
pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).
The following spontaneous adverse events have been reported during the mar-
keting of desloratadine: tachycardia, and rarely hypersensitivity reactions (such as
rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), and elevated liver
enzymes including bilirubin.
DRUG ABUSE AND DEPENDENCE: There is no information to indicate that abuse
or dependency occurs with CLARINEX Tablets.
OVERDOSAGE: Information regarding acute overdosage is limited to experience
from clinical trials conducted during the development of the CLARINEX product. In
a dose ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.
Single daily doses of 45 mg were given to normal male and female volunteers for
10 days. All ECGs obtained in this study were manually read in a blinded fashion by
a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart
rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate
(QTC) by both the Bazett and Fridericia methods. Using the QTC (Bazett) there was a
mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using
QTC (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated sub-
jects relative to placebo. No clinically relevant adverse events were reported.
In the event of overdose, consider standard measures to remove any unabsorbed
drug. Symptomatic and supportive treatment is recommended. Desloratadine and
3-hydroxydesloratadine are not eliminated by hemodialysis.
Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated deslor-
atadine and desloratadine metabolite exposures were approximately 120 times the
AUC in humans at the recommended daily oral dose). The oral median lethal dose
in mice was 353 mg/kg (estimated desloratadine exposures were approximately
290 times the human daily oral dose on a mg/m2 basis). No deaths occurred at oral
doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were
approximately 810 times the human daily oral dose on a mg/m2 basis).
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Homeland Security from page 2
percent (of GNP), and the costs seem more economical,
plus the marked differences in loss of lives! Protection of
the United States and the populace is an invaluable ben-
efit of immense proportion!
Among physicians, many are reluctant to admit the
importance of bioterrorism. Feeling that the public reac-
tion is "hysterical and over reactive." Also, some physi-
cians feel bioterrorism to be uncontrollably fatal and "why
worry?" This debatable attitude is somewhat related to
the slow implementation of civil plans to educate both
the medical establishment and the public on terrorism.
Agreeably, bioterrorism is very difficult to detect, protect,
diagnose, treat, and avoid. Herein lies the basic problem.
The United States Department of Health and Human
Services (HHS) is funding 1.1 billion dollars to state and
local governments to develop programs to combat
bioterrorism and other terrorist-related public health emer-
gencies. An additional 5 billion dollars is proposed for
similar bioterrorism homeland defense in the fiscal year
2003 budget. These funds are earmarked for states'
bioterrorism preparedness, laboratory detection, surveil-
lance, mass casualty response, and drug stockpile and vac-
cine plans. The underlying principle of the initiative is to
aid strengthening of public health programs at the state
and community level. Public education plans are not men-
tioned in the current brief released by the HHS.
The newly formed Defense Science Board now consid-
ers terrorist options such as biologic, chemical, nuclear
missile— and even information technologies— as primary
threats to the US populace. These potential terrorist chal-
lenges to our security are inexpensive and have wide avail-
ability to terrorist groups and rogue nations.
Ease of transportability of terrorist attack modes, com-
bined with the nation's open border policy, are strong con-
tributions to the nation's homeland threat. The Defense
Science Board describes a bioweapon potential such as 220
pounds of bioagent that could kill "one to three million"
people. Another potential but critical threat to the nation
could be the use of "cyber threat," of computer worms or
viruses. Many such instances of failure of our homeland
security perimeter defense can be envisioned, or have al-
ready occurred. The priority of homeland security has now
become a challenge to the entire nation.
The National Nuclear Security Administration (NNSA)
under the United States Energy Department, is tasked to
oversee nuclear terrorism potentials. The total mission is
focused on five potential types of weapons of mass
destruction (WMD):
• vehicular ordinance delivery




The NNSA is addressing these five types of WMD ter-
rorism by developing a population protection means
through "intelligence and warning, prevention, crisis man-
agement, consequence management, and retaliation."The
most severe threat of the above five potentials is radioac-
tive scattering or a fission explosion nuclear attack. The
NNSA is strongly focused on this issue.
Bioterrorism education of the United States' medi-
cal profession has now begun, at national, state, and
county levels. Increased prioritization of awareness is
yet a criticism.
Bioterrorism education of the public falls far behind,
likely due to absent, failed, or weak community programs.
Medical Societies and civil medical health departments
must take a stronger lead in this endeavor. Public aware-
ness is definitely needed to protect society against mass
hysteria, anxiety, fear, insecurity, and other emotionally
uncontrollable scenarios.
Combine the above with the indescribable horror of a
mass bioterrorism attack, and only then can public educa-
tion be invaluable. Educating the public in bioterrorism
must occur through joint efforts of organized medicine
and governmental health bodies.
A syllabus for public education must be developed, by
national leaders. Municipalities should lead in planning
bioterrorism meetings for all public citizens. Civic leaders
must be responsible for assuring public education accom-
plishment. Education of citizens could be through all pub-
lic resources. Full population coverage is imperative.
Factors for emphasis in public information include
bioterrorism subjects, protection advice, local health
sources and authorities, hospital resources, emergency tele-
phone and radio numbers, and immediate emergency
medical care advice to implement until trained medical
aid becomes available.
Education, knowledge, preparation, and awareness are
essential to survival in a bioterrorism attack. All available
resources are vital in facing any terrorist emergency. Na-
tional, state, and community direction is imperative, and
programs for public education and health protection, now
lacking, must be developed rapidly.
/P
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Smallpox from page 1
viable in the lyophilized state. With the dissolution of
the USSR, some 'of the virus may have fallen into un-
reliable or unstable circumstances. The potential is
strong enough, however, that terrorism experts feel that
the deliberate release of smallpox virus is a possibility.
While the threat is not fully known, the vulnerabil-
ity of the United States and virtually the whole world's
population is clear. Individuals born after the mass
immunization program for smallpox was discontinued
in 1972 are not immune. With the exception of cer-
tain populations (e.g., military), those who were born
before 1972 and received the vaccine are likely to have
waning immuni ty with uncer ta in pro tec t ion .
Case-fatality rates could exceed 25 percent if smallpox
were released as a bioterrorism weapon (2). This brings
us to the unfortunate position of making decisions
about mass immunization of an unprotected popula-
tion — not for a naturally occurring pathogen but for
a disease resulting from hatred.
Many other unknowns are involved in this policy
odyssey. Never before have we had to consider the po-
tential for the release of a pathogen previously declared
eradicated from the planet. The well-documented natu-
ral spread of the disease may not be applicable when
the majority of the population has no immunity to
the pathogen, and those vaccinated in the remote past
probably have waning immunity.
Although the incidence of adverse reactions in
healthy individuals is low, the composition and demo-
graphics of the U.S. population have changed signifi-
cantly since the universal vaccine programs of the
mid-20th century. There are now many more
immune-compromised patients in the general popula-
tion. Our experience with universal vaccine programs
took place before the AIDS epidemic, organ transplan-
tation, chronic hemodialysis, extensive cancer chemo-
therapy, and other medical advances that have the sig-
nificant side effects of immune suppression. These sub-
populations are large and growing.
Further, does the United States have the right or
moral imperative to immunize its own population with-
out offering the same opportunity to other countries?
Such decisions must be based on risk of disease expo-
sure and risk of adverse effects of the vaccine in a par-
ticular population. The current Centers for Disease
Control and Prevention (CDC) smallpox plan does not
recommend mass vaccination campaigns in anticipa-
tion of a potential release or in response to documented
cases. For a variety of reasons, public health officials
have taken the position of withholding vaccine that
could effectively protect the public from a terrible dis-
ease until an outbreak is confirmed. The decision in-
volves vaccine availability and safety, the potential ben-
efits and risks of mass pre-exposure vaccination, and
the likelihood of success of postexposure vaccination
programs. The primary benefit of a voluntary mass
immunization would be to reduce the threat of small-
pox as a weapon by reducing the number of suscep-
tible persons. Therefore, an outbreak might be smaller,
more localized, and easier to manage. This strategy al-
lows vaccinations to be carefully planned and methodi-
cal. One of the leading arguments against mass im-
munization is the incidence of adverse effects, some of
which would be severe. An estimated 180 deaths could
occur in a nationwide immunization effort. That esti-
mate is based on adverse events of 1968 and extrapo-
lated to the present population (3). This estimate does
not take into account the increased numbers of indi-
viduals with AIDS or immune suppression from other
causes who could be impacted or the secondary spread
to non-intended populations. Also, the public percep-
tion of immunizations has changed since smallpox vac-
cination programs were widely employed. While vac-
cines have been continually improved to reduce ad-
verse side effects, the public's demands for safety have
become more stringent, and manufacturers' and health
care professionals' liability has increased. While wide
and diverse input should be sought, we must be pre-
pared to support whatever decision is made at the high-
est level. It is reasonable to expect that a final decision
will not be made unless it is forced upon us by events.
The current CDC policy decision is to rely upon
ring vaccinations in the event of a proven case rather
than implementing a universal vaccine program.
Postexposure ring vaccination efficiency depends on
rapid identification of disease, immediate and com-
plete quarantine of exposed persons, and quick identi-
fication and immunization of numerous contacts of
exposed persons and their secondary contacts. Given
the mobility of the population and the frequent venues
Continued —>
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of large crowds and a susceptible population, this ap-
proach might be expected to have limited success in
an intentional multiple-release scenario. A postexposure
strategy could result in managing an outbreak in a cri-
sis operation mode rather than in a carefully orches-
trated preventive plan of action. It is also believed by
some that this crisis implementation of a mass vacci-
nation effort could lead to more adverse events because
of vaccination of immune-compromised individuals or
their exposure to newly immunized individuals.
The public health infrastructure has been "dwin-
dling" over many years. Local expertise and resources
are absolutely essential for the disease surveillance and
outbreak investigation required to identify potential
epidemics as early as possible. An effective response to
an act of terror would require a highly coordinated ef-
fort that would draw upon a multitude of resources.
Health departments, cities, counties, universities,
health science centers, hospitals, and numerous other
entities are engaged in bioterrorism preparedness. The
use of biological agents as weapons could very quickly
expand beyond being a local issue and could certainly
have regional, state, and even national implications.
Planning processes must involve systems approaches
at regional and state levels that feed into national ef-
forts. Each component of emergency response could
function well on its own, but the overall response would
not be effective if the various components did not func-
tion synchronously. It is essential not to undermine
other crucial public health issues as policymakers ad-
dress these issues of bioterrorism. Texas remains last
among the states in childhood immunization rates. Any
effort to address these new problems should not un-
dermine efforts to protect children from known health
threats they face every day. Perhaps a single policy is
not the best policy. To restrict our thinking to "immu-
nize everyone" or "epidemic containment" is too re-
strictive. Perhaps a program in which all health care
professionals and primary responders are offered im-
munizations at screenings or a gradual immunization
of selected groups (e.g., all first graders, all high school
seniors, blood donors, postal workers, Peace Corps
workers) in addition to the military would provide hard
data on complication rates, direct logistic improve-
ments, and over time, lead to a substantial percentage
of immunized individuals. Our challenge is to be
proactive, to act with reason and commitment, to con-
trol our public health destiny, and to use this impetus
to improve disease prevention at all levels.
This policy was driven in part by limited supplies of
vaccine. Recent studies have shown that a diluted vac-
cine can produce an immune response, thus signifi-
cantly extending impact of the available sources (4).
In addition, production of second-generation small-
pox vaccines will increase sup plies to the point that
broader, programs could be implemented. Also, stocks
of old smallpox vaccine have been recently discovered.
Vaccine availability should soon become less of a fac-
tor in policy development. It is clear that once any
decision is made, the information could be very valu-
able to a potential terrorist or adversary as the most
efficient means to work his or her mischief.
All of that said, vaccination is only one component
of an overall system needed to address these public
health threats. Scholars, scientists, politicians, and or-
dinary people are well aware that our world has changed
forever. "Old thinking" will not likely serve us well
when presented with the daunting new problems.
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Changing Face from page 5
findings on a pilot could be a wonderful help to you if
you could have access to it. As I indicated earlier, a good
medical history is your major tool when you are dealing
with a reasonably healthy-appearing individual who may
or may not want to be forthright with you. I very much
hope the FAA can find a way to make a database of at
least major findings available to you to assist you in help-
ing it to maintain aviation safety. You're not just a trans-
mitter of raw data, any more than air traffic controllers
are just monitors, baby-sitting automated ATC systems
(which some would like to make them).
Experts in both professions, medicine and air traffic
management, bring enormous professional experience and
creativity to the tasks they perform—but both need data
and knowledge to make smart decisions in the face of
uncertainty, and both understand the world in which they
work far better than any computer can. Both are in dan-
ger of being "upstaged" by fancy technologies that should
instead be considered simply as tools to help them do
their creative intellectual jobs. This is going to be one of
the major struggles of the coming decade: to recognize
what it is that humans uniquely contribute to highly com-
plex tasks in an ever more automated environment. Tech-
nology experts will tell you that they contribute very little,
and that automation will soon replace them. Don't you
believe it; your jobs are safe for a long time to come,
perhaps forever, despite the cleverness with which auto-
mation can now be applied to parts of those jobs.
Conclusion
So to summarize, where are we? When I say "we," I
mean all of us who form a service component for avia-
tion, a service enterprise. We're under pressure—as is the
enterprise that we support. Our services are absolutely
vital—but we're often viewed as obstacles: part of the
problem rather than part of the solution. We're often
unloved—as is the enterprise that we support, and we
sometimes do less than an optimal job, just as it does.
But aviation is here to stay, and I think we are also here
to stay. There is still a job to be done, just as in aviation's
younger days, and our job is more important because
a lot of our pilot-patients are older and may need more
support to cope with their more complex tasks and
environment.
I don't think for a minute that the cataclysmic changes
with which aviation is now threatened will negate what
we do, nor what our industry does. Aviation is simply
too important in the global marketplace. But I do think
that in the near term, aviation is going to be a more com-
plex and cumbersome system because terrorists have
learned that a transport airplane full of fuel can be a very
effective bomber. Aviation is going to be more expensive
because its infrastructure costs are going to increase con-
siderably in the process of making it a more secure sys-
tem. And aviation professionals and other personnel are
going to need more support, which they may or may not
get from their employers at this time of financial crisis.
They are aviation's most important asset.
I believe we're beginning perhaps the most challeng-
ing period in the history of civil aviation. I hope that
we're up to meeting that challenge, as we have met other
challenges in the past. But doing so is going to require
harder and smarter work from all of us who support the
aviation enterprise, because there is no other professional
group that can perform the services you've been desig-
nated to perform. You are the "force in being" that can
provide aeromedical support to the civil aviation com-
munity and the people who depend on it for essential
transportation services. fP
This article was prepared for the Civil Aviation Medical
Association scientific meeting, Atlanta, Ga., Oct. 11,2001.
The first part was published in the June 2002 Fligh t Physi-
cian. © Charles E. Billings, MD, 2001.
Call for Papers
Your editor is searching for your input into the CAMA F/f'gArPhysician. Needed is an interesting,
challenging, problematic, worrisome, or delaying pilot certification case. All FAA Aviation Medical Ex-
aminers and CAMA physicians experience pilot applicants by the "thousands!" Are there occasions that
develop in your contact with these flyers that fit a picture that would be of interest to your fellow examiners?
Share your memorable cases —short notes or long dissertations! Full credit will be given —or anonymity,
if that is your desire.
—Jim Almand
On The Horizon
Ural mmtKfll &im& BSHBBBBBMBBHHI
Annual Scientific Meeting
The Civil Aviation Medical Association's Annual Scien-
tific Meeting will be held in Amsterdam, the Netherlands, on
October 9-13,2002.
There will be an in-depth look at the role of aircraft as a
disease vector. The program's objective is to assess the epide-
miology of specific infectious diseases in aircraft travel: cos-
mic radiation and aircrew safety, cabin air quality, deep vein
thrombosis and air travel, zoonotic risks of air transportation
of animals, hepatitis in travelers, and bioterrorism.
The Netherlands Society of Aviation Medicine will host
the CAMA meeting. The Mayor of Amsterdam will host the
attendees at a reception at City Hall on Wednesday evening.
There will be a grand tour of the Aeromedical Institute
Soesterberg, with demonstrations of the human centrifuge,
hypobaric chambers, and spatial disorientation. Tours of the
area will be included each afternoon with a farewell canal
cruise on Saturday evening.
This is a program you and the family don't want to miss.
To register for this exciting program contact:
• CAMA Headquarters at (405) 840-0199 or
• Bas Voorsluijs, Seelstraat 69, Utrecht, the Netherlands at
+31 302884317
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FAA Aviation Medical Examiner
Seminar Schedule
2002
September 9-13 Oklahoma City, Okla. (Basic)
December 2-6 Oklahoma City, Okla. (Basic)
2003
January 10-12 Phoenix, Ariz. (Cardiology)
March 10-14 Oklahoma City, Okla. (Basic)
April 25-27 Atlanta, Ga. (Ophth/Otolaryn/Endocrin)
May 5-8 San Antonio, Texas (Neuro/Psychol/Psy)
June 9-13 Oklahoma City, Okla. (Basic)
For information, call your regional flight surgeon. To schedule
a seminar, call the FAA Civil Aerospace Medical Institute
AME Programs Office ( 405) 954-4830
Visit CAMA's Web Site: www.civilavmed.com
CAMA Headquarters
P.O. Box 23864
Oklahoma City, OK 73123-2864
